Abstract

Fluoropyrimidine therapy is a corner-stone of chemotherapeutic management of metastatic cancer. Although only about 15% of patients respond to initial single-agent FUra therapy, a greater number may have disease stabilization with comparatively mild toxicity1,2. Fifteen years ago, we reported that continuous intraportal infusion of Fyra in a significant prolonged survival compared to historical controls3. Since then, significant discoveries of the mechanisms of action of FUra and attempts at rational approaches in its application have been made.